Drug approval (and rejection) highlights from 2012

Another year, another round of approvals, mixed reviews and high-profile failures. We look back on which medicines made the headlines. Read more
Another year, another round of approvals, mixed reviews and high-profile failures. We look back on which medicines made the headlines. Read more
People can be forgiven for thinking that the messages coming out of the American Association for Cancer Research annual meeting in Chicago this week seem to conflict. Finishing up today, the meeting hosted just shy of 17,000 scientists, exhibitors and guests and had several talks expounding the dizzying pace of genome technologies being applied to cancer diagnosis and treatment. At the same time, some speakers warned of the challenges inherent in doing cancer ‘omics.’ … Read more